Literature DB >> 12368706

Treatment of leptomeningeal relapse of medulloblastoma with temozolomide.

Suradej Hongeng, Anannit Visudtibhan, Mantana Dhanachai, Jiraporn Laothamatus, Surang Chiamchanya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12368706     DOI： 10.1097/00043426-200210000-00024

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


× No keyword cloud information.
  4 in total

1.  Medulloblastoma with soft-tissue and skeletal metastases in an adult: A case report.

Authors:  Dianzhong Geng; Xiaohua Song; Jing Liu; Zeshun Yu; Fangling Ning
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

2.  Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.

Authors:  Graziella Cefalo; Maura Massimino; Antonio Ruggiero; Giuseppe Barone; Vita Ridola; Filippo Spreafico; Paolo Potepan; Massimo E Abate; Maurizio Mascarin; Maria Luisa Garrè; Giorgio Perilongo; Enrico Madon; Cesare Colosimo; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

3.  Efficacy of temozolomide for recurrent embryonal brain tumors in children.

Authors:  Chung-Hao Wang; Ting-Rong Hsu; Tai-Tong Wong; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2008-12-24       Impact factor: 1.475

4.  A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.

Authors:  Trent R Hummel; Lars Wagner; Charlotte Ahern; Maryam Fouladi; Joel M Reid; Renee M McGovern; Matthew M Ames; Richard J Gilbertson; Terzah Horton; Ashish M Ingle; Brenda Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2013-03-28       Impact factor: 3.167
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.